BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates
read more...
Jul 23, 2024
BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
read more...
Jul 18, 2024
BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
read more...
Jun 14, 2024
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
read more...
Jun 04, 2024
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
read more...
May 24, 2024
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
read more...
May 14, 2024
BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024
read more...
May 08, 2024
BeiGene Reports First Quarter 2024 Financial Results and Business Updates
read more...
Apr 26, 2024
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
read more...
Apr 24, 2024
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
read more...
Apr 23, 2024
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
read more...
Mar 14, 2024
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
read more...
Mar 13, 2024
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
read more...
Mar 12, 2024
Bringing Light to The Darkness of Cancer: BeiGene Named National Partner of Survivorship and Hope for The Leukemia & Lymphoma Society’s Light The Night
read more...
Mar 07, 2024
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
read more...
Mar 06, 2024
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024
read more...
Feb 29, 2024
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
read more...
Feb 28, 2024
BeiGene to Present at Upcoming Investor Conferences
read more...
Feb 27, 2024
BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
read more...
Feb 26, 2024
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
read more...